This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
In 2013, researchers demonstrated graphene's high mobility in a detector that allows broad band frequency selectivity ranging from the THz to IR region (0.76–33 THz) A separate group created a terahertz-speed transistor with bistable characteristics, which means that the device can spontaneously switch between two electronic states. The device consists of two layers of graphene separated by an insulating layer of boron nitride a few atomic layers thick. Electrons move through this barrier by quantum tunneling. These new transistors exhibit negative differential conductance, whereby the same electric current flows at two different applied voltages. In June, an 8 transistor 1.28 GHz ring oscillator circuit was described. The negative differential resistance experimentally observed in graphene field-effect transistors of conventional design allows for construction of viable non-Boolean computational architectures. The negative differential resistance—observed under certain biasing schemes—is an intrinsic property of graphene resulting from its symmetric band structure. The results present a conceptual change in graphene research and indicate an alternative route for graphene applications in information processing. In 2013 researchers created transistors printed on flexible plastic that operate at 25 gigahertz, sufficient for communications circuits and that can be fabricated at scale. The researchers first fabricated non-graphene-containing structures—the electrodes and gates—on plastic sheets.
Soon after settling into his new home on Riverside Drive, Adorno met with Lazarsfeld in Newark, New Jersey, to discuss the Project's plans for investigating the impact of broadcast music. Although he was expected to embed the Project's research within a wider theoretical context, it soon became apparent that the Project was primarily concerned with data collection to be used by administrators for establishing whether groups of listeners could be targeted by broadcasts specifically aimed at them. Expected to make use of devices with which listeners could press a button to indicate whether they liked or disliked a particular piece of music, Adorno bristled with distaste and astonishment: "I reflected that culture was simply the condition that precluded a mentality that tried to measure it." Thus, Adorno suggested using individual interviews to determine listener reactions and, only three months after meeting Lazarsfeld, completed a 160-page memorandum on the Project's topic, "Music in Radio." Adorno was primarily interested in how musical material was affected by its distribution through the medium of radio and thought it imperative to understand how music was affected by its becoming part of daily life.
=== Oxidative half === In the oxidative half of the mechanism, Cys63 nucleophilically attacks the nearest sulfide unit in the GSSG molecule (promoted by His467), which creates a mixed disulfide bond (GS-Cys58) and a GS− anion. His467 of GSR then protonates the GS- anion to release the first molecule of GSH. Next, Cys63 nucleophilically attacks the sulfide of Cys58, releasing a GS− anion, which, in turn, picks up a solvent proton and is released from the enzyme, thereby creating the second GSH. So, for every GSSG and NADPH, two reduced GSH molecules are gained, which can again act as antioxidants scavenging reactive oxygen species in the cell.
Sources: en.wikipedia.org
Some mammals are omnivores and display varying degrees of carnivory and herbivory, generally leaning in favor of one more than the other. Since plants and meat are digested differently, there is a preference for one over the other, as in bears where some species may be mostly carnivorous and others mostly herbivorous. They are grouped into three categories: mesocarnivory (50–70% meat), hypercarnivory (70% and greater of meat), and hypocarnivory (50% or less of meat). The dentition of hypocarnivores consists of dull, triangular carnassial teeth meant for grinding food. Hypercarnivores, however, have conical teeth and sharp carnassials meant for slashing, and in some cases strong jaws for bone-crushing, as in the case of hyenas, allowing them to consume bones; some extinct groups, notably the Machairodontinae, had saber-shaped canines. Some physiological carnivores consume plant matter and some physiological herbivores consume meat. From a behavioral aspect, this would make them omnivores, but from the physiological standpoint, this may be due to zoopharmacognosy. Physiologically, animals must be able to obtain both energy and nutrients from plant and animal materials to be considered omnivorous. Thus, such animals are still able to be classified as carnivores and herbivores when they are just obtaining nutrients from materials originating from sources that do not seemingly complement their classification. For example, it is well documented that some ungulates such as giraffes, camels, and cattle, will gnaw on bones to consume particular minerals and nutrients.
=== Animal rights === Barker was a vegetarian. In 1982, Barker began ending The Price Is Right episodes with the phrase: "This is Bob Barker reminding you to help control the pet population – have your pets spayed or neutered." Though Barker had already been dabbling in animal rights before meeting Burnet, his efforts became more aggressive during his relationship with her. In 1987, Barker requested the removal of fur prizes for the Miss USA pageant and stepped down as host when the producers refused. In 1989, Barker and United Activists for Animal Rights publicly accused several media projects and the American Humane Association of animal mistreatment and condoning animal mistreatment, a tactic which resulted in a $10 million suit against him and the UAAR for libel, slander, and invasion of privacy. The suit was finally settled by the insurer in 1994. Barker founded DJ&T Foundation in 1994, named after his late wife and mother, which has contributed millions of dollars to animal-neutering programs and funded animal rescue and park facilities all over the United States. In 2004, Barker donated $1 million (equivalent to $1.7 million in 2025) to Columbia Law School to support the study of animal rights. In 2009, Barker wrote a letter about three businesses in Cherokee, North Carolina, asking them to close their bear exhibits. He threatened to not attend the 2009 Game Show Awards, where Barker was to receive a lifetime achievement award, because Betty White would be attending.
== Export == GS-HNE is a potent inhibitor of the activity of glutathione S-transferase, and therefore must be shuttled out of the cell to allow conjugation to occur at a physiological rate. Ral-interacting GTPase activating protein (RLIP76, also known as Ral-binding protein 1), is a membrane-bound protein which has high activity towards the transport of GS-HNE from the cytoplasm to the extracellular space. This protein accounts for approximately 70% of such transport in human cell lines, while the remainder appears to be accounted for by Multidrug Resistance Protein 1 (MRP1).
=== Economics === Trastuzumab costs about US$70,000 for a full course of treatment. Australia has negotiated a lower price of A$50,000 per course of treatment. Since October 2006, trastuzumab has been made available for Australian women and men with early-stage breast cancer via the Pharmaceutical Benefits Scheme. This is estimated to cost the country over A$470 million for 4–5 years supply of the drug. Roche has agreed with Emcure in India to make an affordable version of this cancer drug available to the Indian market. Roche has changed the brand name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately RS75,000 INR (US$ 870) in the Indian market. On 16 September 2014, Genentech notified hospitals in the United States that, as of October, trastuzumab could only be purchased through their selected specialty drugs distributors not through the usual general line wholesalers. By being forced to purchase through specialty pharmacies, hospitals lost rebates from the big wholesalers and the ability to negotiate cost-minus discounts with their wholesalers.
Sources: en.wikipedia.org
In 2024, world production of potatoes was 390 million tonnes, led by China with 24% of the total, and India as a major secondary producer (table). The total area of potatoes harvested in the world in 2024 was 17.1 million hectares (42 million acres).
== Overview == Trails is a series of role-playing video games by Nihon Falcom set in a science fantasy universe. It began as the sixth entry in Falcom's The Legend of Heroes franchise with the release of The Legend of Heroes VI: Trails in the Sky in 2004. Despite that, it had no narrative connection with prior Legend of Heroes games and is considered its own distinct franchise. The Trails games are set within a few years of each other and follow an overarching narrative, with the events of a few entries crossing over into another. The series was conceived by Falcom to have the most ambitious story in video games, with company president and series producer Toshihiro Kondo considering it to be his life's work. The games are made using a proprietary game engine known as the Falcom Developer Kit (FDK), with the exception being Sony's PhyreEngine used for the Trails of Cold Steel games and Trails into Reverie. The series is heavily influenced by anime and features several archetypes and tropes common to it. Trails is set across several locations on the continent of Zemuria, such as the Liberl Kingdom, the city-state of Crossbell, the Erebonian Empire, and the Calvard Republic, among others. Zemuria is home to several groups, factions, and organizations, such as the Bracer's Guild, the Septian Church, the secret society of Ouroboros, mercenary groups known as Jaegers, and several more. The series is set half a century after the discovery of orbal energy, an analog to electric power.
Somali architecture is a rich and diverse tradition of engineering and design. Spanning the country's ancient, medieval and early modern periods, it also embraces the fusion of Somalo-Islamic architecture with contemporary Western designs. In ancient Somalia, pyramidical structures known in Somali as taalo were a popular burial style, with hundreds of these dry stone monuments scattered around the country today. Houses were built of dressed stone similar to the ones in ancient Egypt. There are also examples of courtyards and large stone walls enclosing settlements, such as the Wargaade Wall. The adoption of Islam in Somalia's early medieval history brought Islamic architectural influences from Arabia and Persia. This stimulated a shift in construction from dry stone and other related materials to coral stone, sun dried bricks, and the widespread use of limestone in Somali architecture. Many of the new architectural designs, such as mosques, were built on the ruins of older structures, a practice that would continue throughout the following centuries.
Only certain mezcals, usually from the state of Oaxaca, are ever sold con gusano (with worm). They are added as a marketing gimmick and are not traditional. The tequila regulatory council does not allow gusanos or scorpions (which are sometimes also added to mezcals) to be included in tequila bottles. The worm in some mezcals is actually the larval form of the moth Hypopta agavis, which lives on the agave plant. Finding one in the plant during processing indicates an infestation and, correspondingly, a lower-quality product. The misconception that tequilas may contain worms continues, despite effort and marketing to represent tequila as a premium liquor.
== Side effects == Long term use may result in blepharospasms, especially in women. Doses of 4 mg or more may cause anterograde amnesia. In rare cases, erythema annulare centrifugum skin lesions have resulted.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.